Developing RNAi Therapeutics for Treatment of Cancer & Fibrosis Diseases

READ MORE

LATEST NEWS

April 9, 2020
Sirnaomics Announces Positive Topline Results from Interim Analysis of Ongoing Phase II Clinical Trial Evaluating STP705 in Cutaneous Squamous Cell Carcinoma in situ (isSCC) Sirnaomics Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics... READ MORE
March 20, 2020
Industry, academia pivot: Pipeline of COVID-19 vaccine and therapeutic candidates doubles A list of biopharma companies and nonprofit entities, including academia, working feverishly to find a... READ MORE
February 19, 2020
Hunt for New Coronavirus Treatments Includes Gene-Silencing and Monoclonal Antibodies Viral infections can be very hard to treat. Just ask anyone who has a bad... READ MORE
February 10, 2020
Sirnaomics’ siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today... READ MORE
January 28, 2020
Sirnaomics to develop RNAi-based therapeutics for 2019-nCoV infections The outbreak of 2019-nCov infection, which causes respiratory illness, was first detected in Wuhan City,... READ MORE

Science

Our team uses a consistent, validated approach to develop novel siRNA based therapeutics for significant markets with high unmet clinical need. Using a proprietary algorithm for siRNA sequence prediction against known gene targets we can rapidly identify siRNAs for use against traditionally "non-drugable" targets ...

Read More

Pipeline

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas...

Read More
U.S.A  •  China
© 2007-2019 by Sirnaomics, Inc.
Contact